AP756A - Dipeptide compounds which are growth hormone secretagoques. - Google Patents

Dipeptide compounds which are growth hormone secretagoques. Download PDF

Info

Publication number: AP756A
Authority: AP; ARIPO
Prior art keywords: compounds; group; alkyl; growth hormone; phenyl
Prior art date: 1995-12-28

Application number

APAP/P/1996/000881A

Other languages

English (en)

Other versions

AP9600881A0 (en

Inventor

Philip A Carpino

Silva-Jardine Paul Andrew Da

Bruce Allen Lefker

John A Ragan

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-28

Filing date

1996-11-14

Publication date

1999-08-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21737850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP756(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-11-14 Application filed by Pfizer filed Critical Pfizer

1997-01-31 Publication of AP9600881A0 publication Critical patent/AP9600881A0/xx

1999-08-06 Application granted granted Critical

1999-08-06 Publication of AP756A publication Critical patent/AP756A/en

Links

150000001875 compounds Chemical class 0.000 title abstract description 55
102000018997 Growth Hormone Human genes 0.000 title abstract description 32
108010051696 Growth Hormone Proteins 0.000 title abstract description 32
239000000122 growth hormone Substances 0.000 title abstract description 32
108010016626 Dipeptides Proteins 0.000 title description 4
101710142969 Somatoliberin Proteins 0.000 abstract description 6
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 abstract description 5
150000003839 salts Chemical class 0.000 abstract description 3
238000004519 manufacturing process Methods 0.000 abstract description 2
210000003205 muscle Anatomy 0.000 abstract description 2
230000002265 prevention Effects 0.000 abstract description 2
230000000580 secretagogue effect Effects 0.000 abstract description 2
102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 abstract 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
229940011871 estrogen Drugs 0.000 abstract 2
239000000262 estrogen Substances 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 abstract 1
NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 abstract 1
WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 abstract 1
RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 abstract 1
DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 abstract 1
208000010392 Bone Fractures Diseases 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
208000017667 Chronic Disease Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
230000032683 aging Effects 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
230000001925 catabolic effect Effects 0.000 abstract 1
JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 abstract 1
108010015153 growth hormone releasing hexapeptide Proteins 0.000 abstract 1
108010070965 hexarelin Proteins 0.000 abstract 1
230000013632 homeostatic process Effects 0.000 abstract 1
239000005556 hormone Substances 0.000 abstract 1
229940088597 hormone Drugs 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000012423 maintenance Methods 0.000 abstract 1
230000002503 metabolic effect Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229940063238 premarin Drugs 0.000 abstract 1
239000000186 progesterone Substances 0.000 abstract 1
229960003387 progesterone Drugs 0.000 abstract 1
238000011084 recovery Methods 0.000 abstract 1
230000004044 response Effects 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
230000029663 wound healing Effects 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 description 44
229910052739 hydrogen Inorganic materials 0.000 description 27
239000001257 hydrogen Substances 0.000 description 27
229920006395 saturated elastomer Polymers 0.000 description 20
239000000203 mixture Substances 0.000 description 17
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
125000001424 substituent group Chemical group 0.000 description 15
-1 OCF2H Chemical group 0.000 description 14
229910052760 oxygen Inorganic materials 0.000 description 14
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
229910052757 nitrogen Inorganic materials 0.000 description 12
125000004435 hydrogen atom Chemical group [H]* 0.000 description 11
125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
229910052717 sulfur Chemical group 0.000 description 11
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 10
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
239000001301 oxygen Substances 0.000 description 10
239000011593 sulfur Chemical group 0.000 description 10
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
125000005842 heteroatom Chemical group 0.000 description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
229910052799 carbon Inorganic materials 0.000 description 7
150000002431 hydrogen Chemical class 0.000 description 7
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 6
150000001721 carbon Chemical group 0.000 description 6
229910052736 halogen Inorganic materials 0.000 description 6
150000002367 halogens Chemical class 0.000 description 6
230000028327 secretion Effects 0.000 description 6
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 6
125000003545 alkoxy group Chemical group 0.000 description 5
229910052801 chlorine Inorganic materials 0.000 description 5
229910052731 fluorine Inorganic materials 0.000 description 5
125000001153 fluoro group Chemical group F* 0.000 description 5
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
102100022831 Somatoliberin Human genes 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
125000004433 nitrogen atom Chemical group N* 0.000 description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
206010062767 Hypophysitis Diseases 0.000 description 3
125000005907 alkyl ester group Chemical group 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
125000000753 cycloalkyl group Chemical group 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
125000002883 imidazolyl group Chemical group 0.000 description 3
229940047889 isobutyramide Drugs 0.000 description 3
230000001817 pituitary effect Effects 0.000 description 3
210000003635 pituitary gland Anatomy 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000009467 reduction Effects 0.000 description 3
125000000335 thiazolyl group Chemical group 0.000 description 3
125000006709 (C5-C7) cycloalkenyl group Chemical group 0.000 description 2
125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000008901 benefit Effects 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
210000003016 hypothalamus Anatomy 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
125000001151 peptidyl group Chemical group 0.000 description 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000001544 thienyl group Chemical group 0.000 description 2
WKDBMZQECSVNDS-UHFFFAOYSA-N (2,6-difluorophenyl)-pyrrolidin-1-ylmethanone Chemical compound FC1=CC=CC(F)=C1C(=O)N1CCCC1 WKDBMZQECSVNDS-UHFFFAOYSA-N 0.000 description 1
VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
HCSFWJQLIPWUFZ-JAJWTYFOSA-N 2-(beta-D-glucosyl)-5-methyl-1,3,4-oxadiazole Chemical group O1C(C)=NN=C1[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HCSFWJQLIPWUFZ-JAJWTYFOSA-N 0.000 description 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
229940122361 Bisphosphonate Drugs 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010013883 Dwarfism Diseases 0.000 description 1
102000051325 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
238000008214 LDL Cholesterol Methods 0.000 description 1
UBEBVVBBTDUZKB-WIZGVZBGSA-N N-[(2R)-1-(3a-benzyl-2-ethyl-3-oxo-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-1-oxo-3-phenylmethoxypropan-2-yl]-2-amino-2-methylpropanamide Chemical compound O=C1N(CC)N=C2CCN(C(=O)[C@@H](COCC=3C=CC=CC=3)NC(=O)C(C)(C)N)CC21CC1=CC=CC=C1 UBEBVVBBTDUZKB-WIZGVZBGSA-N 0.000 description 1
CMFDKVQQVCBZTI-DDAUYOFQSA-N N-[(2R)-1-(3a-benzyl-2-ethyl-3-oxo-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-amino-2-methylpropanamide Chemical compound O=C1N(CC)N=C2CCN(C(=O)[C@@H](CC=3C4=CC=CC=C4NC=3)NC(=O)C(C)(C)N)CC21CC1=CC=CC=C1 CMFDKVQQVCBZTI-DDAUYOFQSA-N 0.000 description 1
GWDQWGUUUGDHLC-WIZGVZBGSA-N N-[(2R)-1-[3a-[(4-fluorophenyl)methyl]-2-methyl-3-oxo-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-amino-2-methylpropanamide Chemical compound O=C1N(C)N=C2CCN(C(=O)[C@@H](CC=3C4=CC=CC=C4NC=3)NC(=O)C(C)(C)N)CC21CC1=CC=C(F)C=C1 GWDQWGUUUGDHLC-WIZGVZBGSA-N 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
150000004663 bisphosphonates Chemical class 0.000 description 1
230000037182 bone density Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
230000025938 carbohydrate utilization Effects 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
239000003324 growth hormone secretagogue Substances 0.000 description 1
125000005059 halophenyl group Chemical group 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
230000005541 medical transmission Effects 0.000 description 1
230000004066 metabolic change Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
KVLLHLWBPNCVNR-WZOMIXFGSA-N n-[(2r)-1-(3a-benzyl-2-methyl-3-oxo-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl)-1-oxo-3-phenylmethoxypropan-2-yl]-2-amino-2-methylpropanamide Chemical compound O=C1N(C)N=C2CCN(C(=O)[C@@H](COCC=3C=CC=CC=3)NC(=O)C(C)(C)N)CC21CC1=CC=CC=C1 KVLLHLWBPNCVNR-WZOMIXFGSA-N 0.000 description 1
LNGBRCMHOMMAIO-WZOMIXFGSA-N n-[(2r)-1-(3a-benzyl-2-methyl-3-oxo-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl)-3-[(3,4-difluorophenyl)methoxy]-1-oxopropan-2-yl]-2-amino-2-methylpropanamide Chemical compound O=C1N(C)N=C2CCN(C(=O)[C@@H](COCC=3C=C(F)C(F)=CC=3)NC(=O)C(C)(C)N)CC21CC1=CC=CC=C1 LNGBRCMHOMMAIO-WZOMIXFGSA-N 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000010490 psychological well-being Effects 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
210000001875 somatotroph Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000014616 translation Effects 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Crystallography & Structural Chemistry (AREA)
Neurology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Cooling Or The Like Of Electrical Apparatus (AREA)

APAP/P/1996/000881A 1995-12-28 1996-11-14 Dipeptide compounds which are growth hormone secretagoques. AP756A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US946995P	1995-12-28	1995-12-28

Publications (2)

Publication Number	Publication Date
AP9600881A0 AP9600881A0 (en)	1997-01-31
AP756A true AP756A (en)	1999-08-06

Family

ID=21737850

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
APAP/P/1996/000881A AP756A (en)	1995-12-28	1996-11-14	Dipeptide compounds which are growth hormone secretagoques.
APAP/P/1999/001555A AP860A (en)	1995-12-28	1999-05-27	Dipeptide compounds which are growth hormone secretegoques.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1999/001555A AP860A (en)	1995-12-28	1999-05-27	Dipeptide compounds which are growth hormone secretegoques.

Country Status (43)

Country	Link
US (7)	US6110932A (is)
EP (1)	EP0869968B1 (is)
JP (2)	JP3511382B2 (is)
KR (1)	KR100320167B1 (is)
CN (1)	CN1113895C (is)
AP (2)	AP756A (is)
AR (2)	AR004367A1 (is)
AT (1)	ATE361314T1 (is)
AU (1)	AU716934B2 (is)
BG (1)	BG64055B1 (is)
BR (1)	BR9612465B1 (is)
CA (1)	CA2241725C (is)
CO (1)	CO4480108A1 (is)
CZ (1)	CZ293423B6 (is)
DE (1)	DE69637063T2 (is)
DK (1)	DK0869968T3 (is)
EG (1)	EG24195A (is)
ES (1)	ES2285715T3 (is)
GT (1)	GT199600100A (is)
HN (1)	HN1996000085A (is)
HR (1)	HRP960618B1 (is)
HU (1)	HUP9901246A3 (is)
IL (4)	IL138911A (is)
IS (1)	IS4758A (is)
MA (1)	MA26415A1 (is)
MX (1)	MX9805157A (is)
MY (1)	MY135727A (is)
NO (1)	NO325135B1 (is)
NZ (1)	NZ322172A (is)
OA (1)	OA10702A (is)
PE (1)	PE30398A1 (is)
PL (1)	PL186916B1 (is)
PT (1)	PT869968E (is)
RS (1)	RS49926B (is)
SA (1)	SA97170581B1 (is)
SI (1)	SI0869968T1 (is)
SK (1)	SK285678B6 (is)
TN (1)	TNSN96172A1 (is)
TR (1)	TR199801233T2 (is)
TW (1)	TW432073B (is)
UA (1)	UA66754C2 (is)
WO (1)	WO1997024369A1 (is)
ZA (1)	ZA9610858B (is)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW432073B (en) *	1995-12-28	2001-05-01	Pfizer	Pyrazolopyridine compounds
HN1996000101A (es)	1996-02-28	1997-06-26	Inc Pfizer	Terapia combinada para la osteoporosis
AP2003002729A0 (en)	1997-04-15	2003-06-30	Csir	Pharmaceutical compositions having appetite suppressant activity
GB2324726A (en) *	1997-05-01	1998-11-04	Merck & Co Inc	Combination Therapy for the Treatment of Osteoporosis
DE69837264T2 (de) *	1997-06-25	2008-01-31	Pfizer Inc.	Dipeptidverbindungen, die Wachstumshormon-Sekretagoga sind
UA53716C2 (uk)	1997-06-25	2003-02-17	Пфайзер Продактс Інк.	Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk)	1997-06-25	2004-03-15	Пфайзер Продактс Інк.	Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
US6329342B1 (en)	1997-08-19	2001-12-11	Eli Lilly And Company	Treatment of congestive heart failure with growth hormone secretagogues
ZA987383B (en) *	1997-08-19	2000-02-17	Lilly Co Eli	Treatment of congestive heart failure with growth hormone secretagogues.
US6893877B2 (en)	1998-01-12	2005-05-17	Massachusetts Institute Of Technology	Methods for screening substances in a microwell array
KR20010034198A (ko)	1998-01-16	2001-04-25	한센 핀 베네드	성장 호르몬 방출성을 가지는 화합물
US6657063B1 (en) *	1998-04-30	2003-12-02	Pfizer Inc.	Combinations of β3 agonists and growth hormone secretagogues
CA2334012C (en) *	1998-06-03	2006-05-02	Pfizer Products Inc.	2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
HUP0102395A2 (hu) *	1998-06-16	2001-11-28	Pfizer Products Inc.	Izom- és csontrendszeri gyengeség kezelésére alkalmas szelektív ösztrogén receptor modulátorok és növekedési hormon szekretagógok (GHS) kombinációját tartalmazó gyógyszerkészítmények
PA8475901A1 (es) *	1998-06-16	2000-05-24	Pfizer Prod Inc	Terapia de combinacion para la fragilidad musculoesqueletica
PA8471201A1 (es) *	1998-06-16	2000-09-29	Pfizer Prod Inc	Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
US6639076B1 (en)	1998-08-18	2003-10-28	Eli Lilly And Company	Growth hormone secretagogues
US6358951B1 (en) *	1998-08-21	2002-03-19	Pfizer Inc.	Growth hormone secretagogues
CA2341649A1 (en) *	1998-09-02	2000-03-09	Merck & Co., Inc.	Enhancement of return to independent living status with a growth hormone secretagogue
ES2187195T3 (es)	1998-09-11	2003-05-16	Gerhard Dr Schmidmaier	Implantes biologicamente activos.
US6337332B1 (en)	1998-09-17	2002-01-08	Pfizer Inc.	Neuropeptide Y receptor antagonists
US6380184B1 (en)	1998-10-28	2002-04-30	Bristol-Myers Squibb Co.	Benzoazepines and analogs thereof useful as growth hormone secretagogues
US6194578B1 (en) *	1998-11-20	2001-02-27	Pfizer Inc.	Dipeptide derivatives
SI1004583T1 (en) *	1998-11-23	2004-12-31	Pfizer Products Inc.	Process and hydantoin intermediates for the synthesis of growth hormone secretagogues
US6297380B1 (en)	1998-11-23	2001-10-02	Pfizer Inc.	Process and intermediates for growth hormone secretagogues
EP1158996A4 (en)	1999-02-18	2005-01-12	Kaken Pharma Co Ltd	NEW AMIDE SECRETAGOGUES OF GROWTH HORMONE DERIVATIVES
US6828331B1 (en)	1999-02-19	2004-12-07	Eli Lilly And Company	Growth hormone secretagogues
US6541634B2 (en)	1999-02-26	2003-04-01	Pfizer Inc.	Process for preparing growth hormone secretagogues
US6525203B1 (en)	1999-03-12	2003-02-25	Bristol-Myers Squibb Company	Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6518292B1 (en)	1999-03-12	2003-02-11	Bristol-Myers Squibb Co.	Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
ATE309358T1 (de) *	1999-07-26	2005-11-15	Baylor College Medicine	Superaktive, wachstumshormone freisetzende hormonanaloge vom schwein
GB2355657B (en)	1999-10-27	2004-07-28	Phytopharm Plc	Inhibitors Of Gastric Acid Secretion
EP1113007A1 (en) *	1999-12-24	2001-07-04	Pfizer Inc.	Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
ATE304373T1 (de) *	1999-12-28	2005-09-15	Kaken Pharma Co Ltd	Nervenschutzmittel
CA2400644C (en) *	2000-02-18	2009-07-14	Board Of Trustees Of The Leland Stanford Junior University	Apparatus and methods for parallel processing of micro-volume liquid reactions
US20020151040A1 (en)	2000-02-18	2002-10-17	Matthew O' Keefe	Apparatus and methods for parallel processing of microvolume liquid reactions
EP1132388A3 (en)	2000-03-09	2004-03-03	Pfizer Products Inc.	Hexahydropyrazolo[4,3-c]pyridine metabolites
EP1149583A3 (en) *	2000-04-13	2001-11-14	Pfizer Products Inc.	Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
CA2408486A1 (en)	2000-05-11	2001-11-15	Bristol-Myers Squibb Company	Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
DOP2001000154A (es) *	2000-05-25	2002-05-15	Pfizer Prod Inc	Combinación de secretagogos de hormona del crecimiento y antidepresivos
CA2410597A1 (en)	2000-05-30	2001-12-06	Merck & Co., Inc.	Melanocortin receptor agonists
DE60140285D1 (de) *	2000-05-31	2009-12-10	Pfizer Prod Inc	Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
IL143690A0 (en) *	2000-06-19	2002-04-21	Pfizer Prod Inc	The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
IL143942A0 (en) *	2000-06-29	2002-04-21	Pfizer Prod Inc	Use of growth hormone secretagogues for treatment of physical performance decline
EP1181933A3 (en) *	2000-06-29	2002-04-10	Pfizer Products Inc.	Use of growth hormone secretagogues for stimulating or increasing appetite
GB2363985B (en)	2000-06-30	2004-09-29	Phytopharm Plc	Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144468A0 (en) *	2000-07-27	2002-05-23	Pfizer Prod Inc	Use of growth hormone secretagogues for improvement of functional health status
IL145106A0 (en) *	2000-08-30	2002-06-30	Pfizer Prod Inc	Intermittent administration of a geowth hormone secretagogue
MXPA03001771A (es)	2000-08-30	2003-06-04	Pfizer Prod Inc	Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
IL145540A0 (en) *	2000-09-28	2002-06-30	Pfizer Prod Inc	Use of growth hormone secretagogues in conjunction with physical exercise
EP1330306A2 (en) *	2000-10-10	2003-07-30	BioTrove, Inc.	Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
US20100261159A1 (en)	2000-10-10	2010-10-14	Robert Hess	Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
CA2372450A1 (en) *	2001-05-10	2001-09-19	Pharmaceutical Partners Of Canada Inc.	Liquid injectable formulation of disodium pamidronate
US7125840B2 (en)	2001-10-09	2006-10-24	Eli Lilly And Company	Substituted dipeptides as growth hormone secretagogues
WO2003041641A2 (en)	2001-11-09	2003-05-22	Bristol-Myers Squibb Company	Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US20030199514A1 (en) *	2002-03-27	2003-10-23	Fryburg David A.	Methods for improving efficacy of treatment with growth hormone secretagogues
EP1497316B1 (en)	2002-04-09	2006-07-05	Eli Lilly And Company	Growth hormone secretagogues
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
US8277753B2 (en)	2002-08-23	2012-10-02	Life Technologies Corporation	Microfluidic transfer pin
NZ539218A (en) *	2002-09-18	2008-03-28	Univ Montreal Ct Hospitalier Chum	Synthetic GHRH analogues of 29 amino acids or more
US20060094108A1 (en) *	2002-12-20	2006-05-04	Karl Yoder	Thermal cycler for microfluidic array assays
AU2003302264A1 (en) *	2002-12-20	2004-09-09	Biotrove, Inc.	Assay apparatus and method using microfluidic arrays
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
WO2004108120A1 (en) *	2003-06-11	2004-12-16	Pfizer Products Inc.	Use of growth hormone secretagogues for treatment of fibromyalgia
US7476653B2 (en)	2003-06-18	2009-01-13	Tranzyme Pharma, Inc.	Macrocyclic modulators of the ghrelin receptor
WO2005027913A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
WO2005028438A1 (ja)	2003-09-22	2005-03-31	Banyu Pharmaceutical Co., Ltd.	新規ピペリジン誘導体
US7129561B2 (en) *	2003-11-19	2006-10-31	International Business Machines Corporation	Tri-metal and dual-metal stacked inductors
AU2005222618A1 (en)	2004-03-12	2005-09-29	Biotrove, Inc.	Nanoliter array loading
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
EP1789409A4 (en) *	2004-04-02	2010-09-08	Elixir Pharmaceuticals Inc	SULPHONAMIDES AND ITS USES
WO2005097174A2 (en) *	2004-04-07	2005-10-20	Gastrotech Pharma A/S	Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
RU2007107349A (ru)	2004-07-28	2008-09-10	Глэксо Груп Лимитед (GB)	Пиперазиновые производные, применение для лечения желудочно-кишечных расстройств
US12070731B2 (en)	2004-08-04	2024-08-27	Life Technologies Corporation	Methods and systems for aligning dispensing arrays with microfluidic sample arrays
US20060105453A1 (en) *	2004-09-09	2006-05-18	Brenan Colin J	Coating process for microfluidic sample arrays
WO2006020930A2 (en) *	2004-08-12	2006-02-23	Sapphire Therapeutics, Inc.	Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
EP1781311A4 (en)	2004-08-18	2010-02-17	Elixir Pharmaceuticals Inc	WACHSTUMSHORMONSEKRETAGOGE
NZ562766A (en)	2005-05-30	2011-03-31	Banyu Pharma Co Ltd	Piperidine derivatives as histamine-H3 receptor antagonists
EP1916239A4 (en)	2005-08-10	2009-10-21	Banyu Pharma Co Ltd	PYRIDOLVERBINDUNG
AU2006282260A1 (en)	2005-08-24	2007-03-01	Msd K.K.	Phenylpyridone derivative
US20090264426A1 (en)	2005-09-07	2009-10-22	Shunji Sakuraba	Bicyclic aromatic substituted pyridone derivative
US8293900B2 (en)	2005-09-29	2012-10-23	Merck Sharp & Dohme Corp	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US20080255084A1 (en)	2005-10-21	2008-10-16	Randy Lee Webb	Combination of Organic Compounds
EP1944301A4 (en)	2005-10-27	2012-01-04	Msd Kk	NEW BENZOXATHIIN DERIVATIVES
CA2629018C (en)	2005-11-10	2013-12-31	Banyu Pharmaceutical Co., Ltd.	Aza-substituted spiro derivative
BRPI0618824A2 (pt) *	2005-11-21	2011-09-13	Univ Miyazaki	agente terapêutico acelerador de recuperação dérmica contendo grelina e derivados desta ou substáncias que atuam sobre ghs-r1a como ingrediente ativo
US8273702B2 (en) *	2006-02-17	2012-09-25	Wake Forest University Health Sciences	Wound healing compositions containing keratin biomaterials
CU23558A1 (es)	2006-02-28	2010-07-20	Ct Ingenieria Genetica Biotech	Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CU23592A1 (es) *	2006-02-28	2010-11-11	Ct Ingenieria Genetica Biotech	Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
US20100227806A1 (en)	2006-03-10	2010-09-09	Tulipano Giovanni	Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment
MX2009002492A (es) *	2006-09-08	2009-08-28	Bayer Schering Pharma Ag	Agentes que comprenden compuestos marcados con 18f y metodos relacionados.
EP2698157B1 (en)	2006-09-22	2015-05-20	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
WO2008038692A1 (en)	2006-09-28	2008-04-03	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
WO2008040441A2 (en) *	2006-10-02	2008-04-10	Bayer Schering Pharma Aktiengesellschaft	Silicon derivatives for pet imaging
US20080114055A1 (en) *	2006-11-10	2008-05-15	Zoltan Laboratories Llc	Thioxanthone Compounds to Reverse Weight Loss
EP2644618B1 (en)	2007-02-09	2016-08-17	Ocera Therapeutics, Inc.	tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators
BRPI0721424A2 (pt) *	2007-03-01	2014-03-25	Bayer Schering Pharma Ag	Métodos de radiofluoração
JP2010520913A (ja)	2007-03-12	2010-06-17	サズセアーペーエス	ルイボスの抗糖尿病性抽出物
EP2002835A1 (en)	2007-06-04	2008-12-17	GenKyo Tex	Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US8106086B2 (en)	2007-04-02	2012-01-31	Msd K.K.	Indoledione derivative
MX354786B (es)	2007-06-04	2018-03-21	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2168602A4 (en) *	2007-06-12	2014-10-29	Inst Pharm & Toxicology Amms	LINEAR, PEGYLATED, SITE-SPECIFIC SALMON CALCITONIN DERIVATIVES
EP2264026A4 (en)	2008-03-06	2012-03-28	Msd Kk	ALKYLAMINOPYRIDINDERIVATE
JPWO2009119726A1 (ja)	2008-03-28	2011-07-28	Ｍｓｄ株式会社	メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
CA2726917C (en)	2008-06-04	2018-06-26	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110071129A1 (en)	2008-06-19	2011-03-24	Makoto Ando	Spirodiamine-diaryl ketoxime derivative
EP2321341B1 (en)	2008-07-16	2017-02-22	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (ja)	2008-07-30	2010-02-04	萬有製薬株式会社	５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
EP2166009A1 (en)	2008-09-23	2010-03-24	Genkyo Tex Sa	Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2166010A1 (en)	2008-09-23	2010-03-24	Genkyo Tex Sa	Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2165707A1 (en)	2008-09-23	2010-03-24	Genkyo Tex Sa	Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US8410284B2 (en)	2008-10-22	2013-04-02	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
MX2011004551A (es)	2008-10-30	2011-05-25	Merck Sharp & Dohme	Antagonistas del receptor de orexina de isonicotinamida.
CA2741672A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2305679A1 (en)	2009-09-28	2011-04-06	GenKyoTex SA	Pyrazoline dione derivatives as nadph oxidase inhibitors
EP2361911A1 (en) *	2010-02-18	2011-08-31	GenKyoTex SA	Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361912A1 (en)	2010-02-18	2011-08-31	GenKyoTex SA	Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
AU2011218830B2 (en)	2010-02-25	2014-07-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
ES2615731T3 (es) *	2010-02-26	2017-06-08	Raqualia Pharma Inc.	Agonista del receptor de ghrelina para el tratamiento de caquexia
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en)	2011-02-25	2016-07-26	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
JP6113144B2 (ja) *	2011-04-21	2017-04-12	セラテクノロジーズ・インコーポレーテッド	成長ホルモン放出因子（ｇｒｆ）類似体およびその使用
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
HK1203394A1 (en) *	2012-05-25	2015-10-30	Raqualia Pharma Inc	Ghrelin receptor agonists for the treatment of achlorhydria
RU2015106909A (ru)	2012-08-02	2016-09-27	Мерк Шарп И Доум Корп.	Антидиабетические трициклические соединения
EP2906041A4 (en)	2012-09-27	2016-10-26	Aratana Therapeutics Inc	COMPOSITIONS AND METHODS FOR USE IN A CAPACITY CONNECTOR
CA2889499C (en)	2012-10-24	2019-09-10	Daiichi Sankyo Company, Limited	Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
BR112015019836A2 (pt)	2013-02-22	2017-07-18	Merck Sharp & Dohme	composto, composição farmacêutica, e, uso de um composto
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
WO2014151200A2 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
BR112015029586B1 (pt) *	2013-05-28	2022-05-03	Raqualia Pharma Inc	Formas polimorfas
CN105764916B (zh)	2013-06-05	2021-05-18	博士医疗爱尔兰有限公司	鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
KR102051433B1 (ko) *	2013-08-27	2020-01-08	(주)네오팜	근육 분화 촉진 및 근육 강화용 조성물 및 외용제
US9119832B2 (en)	2014-02-05	2015-09-01	The Regents Of The University Of California	Methods of treating mild brain injury
ES2707124T3 (es) *	2014-08-05	2019-04-02	Raqualia Pharma Inc	Derivados de serina como agonistas del receptor de grelina
MX389591B (es)	2014-08-29	2025-03-20	Tes Pharma S R L	INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
TW201625613A (zh) *	2014-10-31	2016-07-16	拉夸里亞創藥股份有限公司	作為生長激素釋放肽受體激動劑之四氫吡唑並吡啶衍生物
WO2017075535A1 (en)	2015-10-28	2017-05-04	Oxeia Biopharmaceuticals, Inc.	Methods of treating neurodegenerative conditions
MX2019004321A (es)	2016-10-14	2019-06-12	Tes Pharma S R L	Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
EP3479843A1 (en)	2017-11-01	2019-05-08	GenKyoTex Suisse SA	Use of nox inhibitors for treatment of cancer
CN118496217A (zh)	2018-11-20	2024-08-16	Tes制药有限责任公司	α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
CN109320515A (zh) *	2018-11-22	2019-02-12	常州大学	一种Capromorelin手性中间体的不对称合成方法
EP3924058B1 (en)	2019-02-13	2026-01-07	Merck Sharp & Dohme LLC	5-alkyl pyrrolidine orexin receptor agonists
WO2024217441A1 (zh) *	2023-04-21	2024-10-24	长春金赛药业有限责任公司	GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) *	2024-10-09	2025-01-10	威海中腾医药科技有限公司	一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995013069A1 (en) *	1993-11-09	1995-05-18	Merck & Co., Inc.	Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
EP0662481A1 (en) *	1992-12-11	1995-07-12	Merck & Co. Inc.	Spiro piperidines and homologs promote release of growth hormone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK139625B (da) *	1971-05-11	1979-03-19	Sandoz Ag	Analogifremgangsmåde til fremstilling af cycloalkan(c)pyridazin- eller pyrido(4,3-c)pyridazinderivater eller syreadditionssalte deraf.
DE2221808C2 (de) *	1972-05-04	1985-06-20	Sandoz-Patent-GmbH, 7850 Lörrach	Hydrazinopyridazin-Derivate, deren Säureadditionssalze, Verfahren zu deren Herstellung und Heilmittel
JP3670690B2 (ja) *	1993-10-04	2005-07-13	トーアエイヨー株式会社	３−ピリダジノン誘導体、その製造法およびそれを含有する循環器官用剤
FI961681L (fi) *	1993-10-19	1996-06-12	Merck & Co Inc	Bisfosfonaattien ja kasvuhormoonin eritystä lisäävien aineiden yhdistelmä
US5610134A (en) *	1994-04-15	1997-03-11	Genentech, Inc.	Treatment of congestive heart failure
US5935924A (en) *	1994-04-15	1999-08-10	Genentech, Inc.	Treatment of congestive heart failure
US5767118A (en) *	1994-10-26	1998-06-16	Merck & Co., Inc.	4-Heterocyclic peperidines promote release of growth hormone
US5798337A (en) *	1994-11-16	1998-08-25	Genentech, Inc.	Low molecular weight peptidomimetic growth hormone secretagogues
AU705744B2 (en) *	1995-01-27	1999-06-03	Sapphire Therapeutics, Inc.	Compounds with growth hormone releasing properties
WO1996024580A1 (en) *	1995-02-09	1996-08-15	Novo Nordisk A/S	Compounds with growth hormone releasing properties
AU4534696A (en) *	1995-02-09	1996-08-27	Novo Nordisk A/S	Compounds with growth hormone releasing properties
EP0761220A1 (en) *	1995-08-21	1997-03-12	Eli Lilly And Company	2-Acylaminopropanamides as growth hormone secretagogues
AU6724496A (en) *	1995-08-21	1997-03-12	Eli Lilly And Company	2-acylaminopropanamines as growth hormone secretagogues
TW432073B (en)	1995-12-28	2001-05-01	Pfizer	Pyrazolopyridine compounds
US6020358A (en) *	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels

1996
- 1996-11-13 TW TW085113857A patent/TW432073B/zh not_active IP Right Cessation
- 1996-11-14 AP APAP/P/1996/000881A patent/AP756A/en active
- 1996-12-04 DE DE69637063T patent/DE69637063T2/de not_active Expired - Lifetime
- 1996-12-04 PT PT96938434T patent/PT869968E/pt unknown
- 1996-12-04 JP JP52412497A patent/JP3511382B2/ja not_active Expired - Lifetime
- 1996-12-04 AT AT96938434T patent/ATE361314T1/de not_active IP Right Cessation
- 1996-12-04 CN CN96199388A patent/CN1113895C/zh not_active Expired - Lifetime
- 1996-12-04 ES ES96938434T patent/ES2285715T3/es not_active Expired - Lifetime
- 1996-12-04 PL PL96327634A patent/PL186916B1/pl not_active IP Right Cessation
- 1996-12-04 SI SI9630755T patent/SI0869968T1/sl unknown
- 1996-12-04 CZ CZ19981995A patent/CZ293423B6/cs not_active IP Right Cessation
- 1996-12-04 HU HU9901246A patent/HUP9901246A3/hu unknown
- 1996-12-04 NZ NZ322172A patent/NZ322172A/xx unknown
- 1996-12-04 IL IL138911A patent/IL138911A/en not_active IP Right Cessation
- 1996-12-04 TR TR1998/01233T patent/TR199801233T2/xx unknown
- 1996-12-04 IL IL13891096A patent/IL138910A0/xx unknown
- 1996-12-04 IL IL12444996A patent/IL124449A/en not_active IP Right Cessation
- 1996-12-04 BR BRPI9612465-2A patent/BR9612465B1/pt not_active IP Right Cessation
- 1996-12-04 IL IL13890996A patent/IL138909A0/xx unknown
- 1996-12-04 WO PCT/IB1996/001353 patent/WO1997024369A1/en not_active Ceased
- 1996-12-04 AU AU75850/96A patent/AU716934B2/en not_active Ceased
- 1996-12-04 EP EP96938434A patent/EP0869968B1/en not_active Expired - Lifetime
- 1996-12-04 CA CA002241725A patent/CA2241725C/en not_active Expired - Lifetime
- 1996-12-04 DK DK96938434T patent/DK0869968T3/da active
- 1996-12-04 SK SK874-98A patent/SK285678B6/sk not_active IP Right Cessation
- 1996-12-04 UA UA98063368A patent/UA66754C2/xx unknown
- 1996-12-04 KR KR10-1998-0704973A patent/KR100320167B1/ko not_active Expired - Lifetime
- 1996-12-06 HN HN1996000085A patent/HN1996000085A/es unknown
- 1996-12-09 AR ARP960105571A patent/AR004367A1/es active IP Right Grant
- 1996-12-19 GT GT199600100A patent/GT199600100A/es unknown
- 1996-12-20 CO CO96066996A patent/CO4480108A1/es unknown
- 1996-12-23 ZA ZA9610858A patent/ZA9610858B/xx unknown
- 1996-12-24 TN TNTNSN96172A patent/TNSN96172A1/fr unknown
- 1996-12-24 MA MA24438A patent/MA26415A1/fr unknown
- 1996-12-24 EG EG117796A patent/EG24195A/xx active
- 1996-12-26 MY MYPI96005499A patent/MY135727A/en unknown
- 1996-12-26 RS YUP-702/96A patent/RS49926B/sr unknown
- 1996-12-27 HR HR960618A patent/HRP960618B1/xx not_active IP Right Cessation
- 1996-12-27 PE PE1996000961A patent/PE30398A1/es not_active Application Discontinuation
1997
- 1997-01-27 SA SA97170581A patent/SA97170581B1/ar unknown
1998
- 1998-05-26 IS IS4758A patent/IS4758A/is unknown
- 1998-06-11 BG BG102533A patent/BG64055B1/bg unknown
- 1998-06-19 OA OA9800090A patent/OA10702A/en unknown
- 1998-06-24 MX MX9805157A patent/MX9805157A/es active IP Right Grant
- 1998-06-26 NO NO19982991A patent/NO325135B1/no not_active IP Right Cessation
1999
- 1999-03-01 US US09/258,956 patent/US6110932A/en not_active Expired - Lifetime
- 1999-03-01 US US09/259,691 patent/US6107306A/en not_active Expired - Lifetime
- 1999-03-01 US US09/259,776 patent/US6124264A/en not_active Expired - Lifetime
- 1999-05-27 AP APAP/P/1999/001555A patent/AP860A/en active
- 1999-12-22 US US09/470,668 patent/US6278000B1/en not_active Expired - Lifetime
2000
- 2000-06-13 US US09/593,582 patent/US6306875B1/en not_active Expired - Lifetime
- 2000-06-13 US US09/593,581 patent/US6313140B1/en not_active Expired - Lifetime
- 2000-12-11 US US09/734,274 patent/US6482825B2/en not_active Expired - Lifetime
- 2000-12-20 JP JP2000386997A patent/JP2001213800A/ja active Pending
2006
- 2006-03-03 AR ARP060100824A patent/AR052506A2/es active IP Right Grant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0662481A1 (en) *	1992-12-11	1995-07-12	Merck & Co. Inc.	Spiro piperidines and homologs promote release of growth hormone
WO1995013069A1 (en) *	1993-11-09	1995-05-18	Merck & Co., Inc.	Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone

Also Published As

Publication number	Publication date
HUP9901246A2 (hu)	1999-08-30
IS4758A (is)	1998-05-26
HUP9901246A3 (en)	1999-11-29
CN1113895C (zh)	2003-07-09
ATE361314T1 (de)	2007-05-15
JP3511382B2 (ja)	2004-03-29
AR004367A1 (es)	1998-11-04
RS49926B (sr)	2008-09-29
CN1206422A (zh)	1999-01-27
IL138911A (en)	2007-07-24
PL186916B1 (pl)	2004-03-31
AP9901555A0 (en)	1999-06-30
BG102533A (en)	1999-09-30
JPH11501945A (ja)	1999-02-16
AU716934B2 (en)	2000-03-09
IL138909A0 (en)	2001-11-25
US6313140B1 (en)	2001-11-06
PT869968E (pt)	2007-07-11
US6482825B2 (en)	2002-11-19
TR199801233T2 (xx)	1998-10-21
CZ293423B6 (cs)	2004-04-14
HN1996000085A (es)	1997-06-18
NZ322172A (en)	2000-08-25
US6107306A (en)	2000-08-22
AU7585096A (en)	1997-07-28
DK0869968T3 (da)	2007-09-10
UA66754C2 (en)	2004-06-15
TNSN96172A1 (fr)	2005-03-15
DE69637063D1 (de)	2007-06-14
BR9612465B1 (pt)	2010-08-10
KR19990076846A (ko)	1999-10-25
SA97170581B1 (ar)	2006-03-15
MA26415A1 (fr)	2004-12-20
CZ199598A3 (cs)	1999-05-12
EG24195A (en)	2008-10-14
US6306875B1 (en)	2001-10-23
MY135727A (en)	2008-06-30
KR100320167B1 (ko)	2003-11-14
IL138910A0 (en)	2001-11-25
EP0869968B1 (en)	2007-05-02
NO982991D0 (no)	1998-06-26
US6278000B1 (en)	2001-08-21
CO4480108A1 (es)	1997-07-09
SI0869968T1 (sl)	2007-08-31
SK87498A3 (en)	1999-08-06
WO1997024369A1 (en)	1997-07-10
AP860A (en)	1999-08-06
PE30398A1 (es)	1998-07-21
MX9805157A (es)	1998-10-31
CA2241725A1 (en)	1997-07-10
NO982991L (no)	1998-08-26
OA10702A (en)	2001-05-07
SK285678B6 (sk)	2007-06-07
BR9612465A (pt)	1999-07-13
JP2001213800A (ja)	2001-08-07
HRP960618A2 (en)	1998-04-30
ZA9610858B (en)	1998-06-23
IL138911A0 (en)	2001-11-25
TW432073B (en)	2001-05-01
EP0869968A1 (en)	1998-10-14
HRP960618B1 (en)	2007-12-31
IL124449A (en)	2004-06-01
GT199600100A (es)	1998-06-12
YU70296A (en)	1999-11-22
BG64055B1 (bg)	2003-11-28
US6124264A (en)	2000-09-26
CA2241725C (en)	2002-06-18
NO325135B1 (no)	2008-02-04
PL327634A1 (en)	1998-12-21
AR052506A2 (es)	2007-03-21
US20020049196A1 (en)	2002-04-25
IL124449A0 (en)	1998-12-06
US6110932A (en)	2000-08-29
DE69637063T2 (de)	2008-02-07
AP9600881A0 (en)	1997-01-31
ES2285715T3 (es)	2007-11-16

Publication	Publication Date	Title
AP756A (en)	1999-08-06	Dipeptide compounds which are growth hormone secretagoques.
JP5000848B2 (ja)	2012-08-15	グレリン含有医薬組成物
ES2333097T3 (es)	2010-02-17	Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
US6313133B1 (en)	2001-11-06	Sleep quality improvement using a growth hormone secretagogue
US20230120030A1 (en)	2023-04-20	Long-Acting Adrenomedullin Derivatives
EP3271015B1 (en)	2023-09-27	Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
JPH10509152A (ja)	1998-09-08	低分子量ペプチド様成長ホルモン放出促進物質
TWI861780B (zh)	2024-11-11	預防或治療肥胖的聯合療法
AU711884B2 (en)	1999-10-21	Enhancement of sleep with a growth hormone secretagogue
WO2006023608A2 (en)	2006-03-02	Growth-hormone secretagogues
AU2004281084B2 (en)	2010-08-12	Use of growth hormone releasing factor analogs in treating patients suffering from wasting
AU2003229724B2 (en)	2009-07-02	Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
WO2001089570A2 (en)	2001-11-29	Combination of growth hormone secretagogues and antidepressants
KR101228229B1 (ko)	2013-01-31	성장 호르몬 분비 촉진물질 및 그의 용도
AU6133299A (en)	2000-03-21	Enhancement of return to independent living status with a growth hormone secretagogue
CA2335112A1 (en)	1999-12-23	Therapeutic combinations for musculoskeletal frailty
US20020160961A1 (en)	2002-10-31	Compositions for the treatment of the catabolic state of prolonged critical illness
EP1716887B1 (en)	2008-03-19	Treatment of inclusion body myositis
RU2172742C2 (ru)	2001-08-27	Стимуляторы секреции гормона роста
RU98112108A (ru)	2000-07-20	Стимуляторы секреции гормона роста
EA044055B1 (ru)	2023-07-20	Применение антагониста рецептора нейрокинина-3 (nk-3) для повышения уровней циркулирующего лептина у пациентов
HK1036938A (en)	2002-01-25	Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty